Illumina | GenomeWeb

Illumina

 

Illumina is a developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. Illumina has developed a line of products that address the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests.

Illumina Facts

 

CEO: Jay Flatley

Website: www.illumina.com

Ticker symbol: ILMN

Headquarters: San Diego, CA

Number of employees: 3,750+ globally

The bank rated companies like Thermo Fisher Scientific and Agilent at Buy, Illumina and PerkinElmer at Hold, and Myriad Genetics and Luminex at Sell.

Under the terms of the deals, Illumina and Monsanto will have access to NRGene's genome assembly and analysis technologies for ag-bio research projects.

Systems will ship in early February and include droplet-based library prep and analytics functionalities.

The company also announced a 5 percent increase in preliminary fourth quarter revenues, to $619 million and above analysts' estimates.

The collaborations aim to combine Illumina's sequencing systems with Philips' IntelliSpace Genomics platform and with IBM's Watson for Genomics, respectively.

Illumina plans to speed up the process of making Grail an independent company and will no longer have representation on its board of directors. 

It was a rough year for biotech stocks — the Nasdaq Biotech Index fell 22 percent even as the Dow gained 13 percent and the Nasdaq gained 8 percent.

The organization will promote public awareness of cfDNA-based NIPT, encourage legislation supporting testing, and push for reimbursement policy changes.

The partners have opened a new biorepository that will engage with clinical researchers and foster future personalized medicine efforts in the German capital.

Pages

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.